Abstract
Obesity is a major risk factor for a wide range of cardimetabolic diseases. As its genetic determinants have become increasingly elucidated, it has become feasible to investigate its health consequences via Mendelian randomisation (MR). To study the impact of different aspects of body morphology on health outcomes, we gathered fourteen body morphology measures and associated GWAS summary statistics from UK Biobank and used principal component analysis to reveal four major independent axes of genetically driven variation in body shape and size: overall body size, adiposity, predisposition to abdominal fat deposition, and lean mass. Enrichment analyses suggest that body size and adiposity are affected by genes involved in neuronal signalling, whereas body fat distribution and lean mass are dependent on genes involved in morphogenesis and energy homeostasis. Using MR, we found that the adiposity component had the strongest impact on cardiometabolic health and obesityrelated diseases and its genetic basis was intertwined with aspects of lower socio-economic status (SES). Overall body size affected many of the same diseases in an independent manner, but was linked to a more sedentary lifestyle with no change in SES. The body mass-neutral component predisposing to abdominal fat deposition, likely reflecting a shift from subcutaneous to visceral fat, exhibited health effects that were weaker but more specifically linked to lipotoxicity, such as diabetes and heart disease. The presented decomposition approach sheds light on the biological mechanisms underlying the remarkably heterogeneous nature of body morphology as well as its consequences on health and lifestyle.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank resource (#16389). The computations have been carried out on the HPC server of the Lausanne University Hospital. Z.K. was funded by the Swiss National Science Foundation (31003A-143914 and 310030-189147). B.D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant Nr. 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185) and the Leenaards Foundation. LREN is very grateful to the Roger De Spoelberch and Partridge Foundations for their generous financial support. T.O.K. was funded by the Novo Nordisk Foundation (NNF17OC0026848, NNF18CC0034900).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was performed using the UK Biobank resource (#16389), which has been approved by the National Research Ethics Service Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data was provided by the UK Biobank and the Neale lab.
